Zacks: Kura Oncology Inc. (NASDAQ:KURA) Receives Average Recommendation of “Strong Buy” from Analysts
Kura Oncology Inc. (NASDAQ:KURA) has earned an average broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy recommendation.
Brokerages have set a 1 year consensus price target of $20.00 for the company and are anticipating that the company will post ($0.41) earnings per share for the current quarter, according to Zacks. Zacks has also given Kura Oncology an industry rank of 91 out of 265 based on the ratings given to its competitors.
A number of equities research analysts have recently commented on KURA shares. Oppenheimer Holdings Inc. reaffirmed an “outperform” rating and set a $16.00 price target on shares of Kura Oncology in a research report on Tuesday, June 21st. Zacks Investment Research raised Kura Oncology from a “hold” rating to a “buy” rating and set a $3.75 target price on the stock in a research report on Wednesday, July 13th.
A hedge fund recently bought a new stake in Kura Oncology stock. Alethea Capital Management LLC bought a new position in shares of Kura Oncology Inc. (NASDAQ:KURA) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 62,000 shares of the company’s stock, valued at approximately $168,000. Alethea Capital Management LLC owned about 0.34% of Kura Oncology at the end of the most recent reporting period. 43.63% of the stock is currently owned by institutional investors.
Shares of Kura Oncology (NASDAQ:KURA) opened at 7.05 on Tuesday. The company’s market cap is $132.14 million. Kura Oncology has a 12 month low of $2.50 and a 12 month high of $25.00. The firm’s 50-day moving average price is $5.61 and its 200-day moving average price is $3.99.
Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Wednesday, August 10th. The company reported ($0.36) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.34) by $0.02. Equities analysts predict that Kura Oncology will post ($1.58) EPS for the current fiscal year.
About Kura Oncology
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.